Thus, our aim was to reveal if MSC senescence induction by pre‐treatment with CCL2 could alter differentially the sensitivity of leukemic cells to the different cytotoxic drugs used in B‐ALL patients. The gene discussed is CCL2; the disease is acute lymphoblastic leukemia.